Max Robotics — Global Service Robot Directory + US Certification

About

Joris G. Heetman is a clinical researcher advancing the role of molecular imaging in prostate cancer management. His work centers on improving diagnostic precision and prognostic accuracy through the integration of PSMA PET/CT and MRI into clinical nomograms. Heetman’s major contributions include the external validation of MRI-based nomograms for predicting side-specific extraprostatic extension (2023, 10 citations), a critical step toward personalized surgical planning. He has also pioneered the use of PSMA PET/CT for local staging, demonstrating its superior performance over conventional imaging in predicting biochemical recurrence after radical prostatectomy (2025, 3 citations). In a landmark immunohistochemical and histopathological validation study (2023, 3 citations), he confirmed that ¹⁸F-PSMA-1007 PET/CT accurately identifies intraprostatic cancerous lesions, directly correlating tracer uptake with PSMA overexpression in tumor tissue. This foundational work bridges molecular imaging and pathology, offering a more reliable basis for targeted biopsies and focal therapy. Heetman’s research is shaping next-generation staging algorithms, with his externally validated nomograms already informing clinical decision-making. His findings underscore the transformative potential of PSMA PET/CT in redefining risk stratification and improving outcomes for prostate cancer patients.